Bio-Matrix Scientific's Research Subsidiary, Entest BioMedical, Inc., Files Stem Cell Therapy Patent Application For Treatment Of COPD
Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy.
[Read the full article here]Related News:
Bio-Matrix Scientific Group’s Majority Owned Subsidiary Entest BioMedical Initiates Studies To Support Stem Cell / Laser Regenerative Therapy For COPD
Entest BioMedical Files Patent Application On Chemokine Technology To Increase Efficacy Of Tissue-Specific Stem Cell Homing In COPD Treatment
Entest BioMedical Files 3rd Patent Application for COPD Stem Cell …